Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
Samsara BioCapital
AI-generated illustration
OrganisationUS

Samsara BioCapital

Palo Alto biotech investor; joined Cambridge spinout T-Therapeutics' $133m Series B in 2026.

Last refreshed: 14 November 2026 · Appears in 1 active topic

Key Question

Why are American biotech specialists funding Cambridge T-cell drugs?

Timeline for Samsara BioCapital

#17 5 Nov

Joined T-Therapeutics' Series B

UK Startups and Innovation: T-Therapeutics raises $133m in Series B
View full timeline →

Background

Samsara BioCapital joined T-Therapeutics' $133m Series B on 5 November 2026 as a new investor. Advent Life Sciences and the British Business Bank co-led the round, and Eli Lilly, Johnson & Johnson Innovation and M Ventures also joined.

Samsara is a biotech investment firm based in Palo Alto, California, founded by Srinivas Akkaraju. It invests in companies turning new biology into drugs for patients with unmet needs.

The Register shows why Cambridge spinouts look abroad: no single British investor class will fund drug development to clinical proof of concept on its own.

Common Questions
Who is Samsara BioCapital?
A Palo Alto biotech investment firm founded by Srinivas Akkaraju. In November 2026 it joined T-Therapeutics' $133m Series B.Source: BioPharm International
Who invested in T-Therapeutics' Series B?
Advent Life Sciences and the British Business Bank co-led it; Eli Lilly, Johnson & Johnson Innovation, Samsara BioCapital and M Ventures joined.Source: BioPharm International
Where is Samsara BioCapital based?
In Palo Alto, California.Source: Samsara BioCapital
Source Material

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Updated 14 November 2026. Editorial standards.